rvnc-20210930
0001479290December 312021Q3FALSEhttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Memberhttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member0.030880400014792902021-01-012021-09-30xbrli:shares00014792902021-10-28iso4217:USD00014792902021-09-3000014792902020-12-31iso4217:USDxbrli:shares0001479290us-gaap:ProductMember2021-07-012021-09-300001479290us-gaap:ProductMember2020-07-012020-09-300001479290us-gaap:ProductMember2021-01-012021-09-300001479290us-gaap:ProductMember2020-01-012020-09-300001479290rvnc:CollaborationRevenueMember2021-07-012021-09-300001479290rvnc:CollaborationRevenueMember2020-07-012020-09-300001479290rvnc:CollaborationRevenueMember2021-01-012021-09-300001479290rvnc:CollaborationRevenueMember2020-01-012020-09-300001479290us-gaap:ServiceMember2021-07-012021-09-300001479290us-gaap:ServiceMember2020-07-012020-09-300001479290us-gaap:ServiceMember2021-01-012021-09-300001479290us-gaap:ServiceMember2020-01-012020-09-3000014792902021-07-012021-09-3000014792902020-07-012020-09-3000014792902020-01-012020-09-300001479290us-gaap:PreferredStockMember2021-06-300001479290us-gaap:PreferredStockMember2020-06-300001479290us-gaap:PreferredStockMember2020-09-300001479290us-gaap:PreferredStockMember2020-12-310001479290us-gaap:PreferredStockMember2019-12-310001479290us-gaap:CommonStockMember2021-06-300001479290us-gaap:CommonStockMember2020-06-300001479290us-gaap:CommonStockMember2020-12-310001479290us-gaap:CommonStockMember2019-12-310001479290us-gaap:CommonStockMember2021-07-012021-09-300001479290us-gaap:CommonStockMember2020-07-012020-09-300001479290us-gaap:CommonStockMember2021-01-012021-09-300001479290us-gaap:CommonStockMember2020-01-012020-09-300001479290us-gaap:CommonStockMember2021-09-300001479290us-gaap:CommonStockMember2020-09-300001479290us-gaap:AdditionalPaidInCapitalMember2021-06-300001479290us-gaap:AdditionalPaidInCapitalMember2020-06-300001479290us-gaap:AdditionalPaidInCapitalMember2020-12-310001479290us-gaap:AdditionalPaidInCapitalMember2019-12-3100014792902020-01-012020-12-310001479290srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2020-12-310001479290us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001479290us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001479290us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001479290us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001479290rvnc:FollowOnOfferingMember2020-01-012020-09-300001479290us-gaap:AdditionalPaidInCapitalMember2021-09-300001479290us-gaap:AdditionalPaidInCapitalMember2020-09-300001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001479290us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001479290us-gaap:RetainedEarningsMember2021-06-300001479290us-gaap:RetainedEarningsMember2020-06-300001479290us-gaap:RetainedEarningsMember2020-12-310001479290us-gaap:RetainedEarningsMember2019-12-310001479290us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310001479290us-gaap:RetainedEarningsMember2021-07-012021-09-300001479290us-gaap:RetainedEarningsMember2020-07-012020-09-300001479290us-gaap:RetainedEarningsMember2021-01-012021-09-300001479290us-gaap:RetainedEarningsMember2020-01-012020-09-300001479290us-gaap:RetainedEarningsMember2021-09-300001479290us-gaap:RetainedEarningsMember2020-09-3000014792902020-09-3000014792902019-12-310001479290srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-01-010001479290us-gaap:ProductMemberus-gaap:TransferredAtPointInTimeMember2021-07-012021-09-300001479290us-gaap:TransferredAtPointInTimeMemberrvnc:CollaborationRevenueMember2021-07-012021-09-300001479290us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2021-07-012021-09-300001479290us-gaap:TransferredAtPointInTimeMember2021-07-012021-09-300001479290us-gaap:ProductMemberus-gaap:TransferredAtPointInTimeMember2021-01-012021-09-300001479290us-gaap:TransferredAtPointInTimeMemberrvnc:CollaborationRevenueMember2021-01-012021-09-300001479290us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2021-01-012021-09-300001479290us-gaap:TransferredAtPointInTimeMember2021-01-012021-09-300001479290us-gaap:ProductMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300001479290us-gaap:TransferredOverTimeMemberrvnc:CollaborationRevenueMember2021-07-012021-09-300001479290us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2021-07-012021-09-300001479290us-gaap:TransferredOverTimeMember2021-07-012021-09-300001479290us-gaap:ProductMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300001479290us-gaap:TransferredOverTimeMemberrvnc:CollaborationRevenueMember2021-01-012021-09-300001479290us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2021-01-012021-09-300001479290us-gaap:TransferredOverTimeMember2021-01-012021-09-300001479290us-gaap:ProductMemberus-gaap:TransferredAtPointInTimeMember2020-07-012020-09-300001479290us-gaap:TransferredAtPointInTimeMemberrvnc:CollaborationRevenueMember2020-07-012020-09-300001479290us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2020-07-012020-09-300001479290us-gaap:TransferredAtPointInTimeMember2020-07-012020-09-300001479290us-gaap:ProductMemberus-gaap:TransferredAtPointInTimeMember2020-01-012020-09-300001479290us-gaap:TransferredAtPointInTimeMemberrvnc:CollaborationRevenueMember2020-01-012020-09-300001479290us-gaap:ServiceMemberus-gaap:TransferredAtPointInTimeMember2020-01-012020-09-300001479290us-gaap:TransferredAtPointInTimeMember2020-01-012020-09-300001479290us-gaap:ProductMemberus-gaap:TransferredOverTimeMember2020-07-012020-09-300001479290us-gaap:TransferredOverTimeMemberrvnc:CollaborationRevenueMember2020-07-012020-09-300001479290us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2020-07-012020-09-300001479290us-gaap:TransferredOverTimeMember2020-07-012020-09-300001479290us-gaap:ProductMemberus-gaap:TransferredOverTimeMember2020-01-012020-09-300001479290us-gaap:TransferredOverTimeMemberrvnc:CollaborationRevenueMember2020-01-012020-09-300001479290us-gaap:ServiceMemberus-gaap:TransferredOverTimeMember2020-01-012020-09-300001479290us-gaap:TransferredOverTimeMember2020-01-012020-09-300001479290us-gaap:ProductMember2021-09-300001479290us-gaap:ProductMember2020-12-310001479290rvnc:ViatrisMember2021-09-300001479290rvnc:ViatrisMember2021-01-012021-09-300001479290rvnc:DevelopmentServicesMember2021-07-012021-09-300001479290rvnc:DevelopmentServicesMember2021-01-012021-09-300001479290rvnc:DevelopmentServicesMember2020-07-012020-09-300001479290rvnc:DevelopmentServicesMember2020-01-012020-09-300001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2021-09-300001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2019-01-310001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2020-01-012020-09-300001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2020-07-012020-09-300001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2021-07-012021-09-300001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2021-01-012021-09-300001479290rvnc:ViatrisMember2020-12-310001479290rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member2020-12-310001479290us-gaap:ServiceMember2021-09-300001479290us-gaap:ServiceMember2020-12-310001479290rvnc:HintMDMember2020-07-012020-09-300001479290rvnc:HintMDMember2020-01-012020-09-300001479290rvnc:HintMDMember2019-01-012019-03-310001479290us-gaap:MoneyMarketFundsMember2021-09-300001479290us-gaap:MoneyMarketFundsMember2020-12-310001479290us-gaap:CommercialPaperMember2021-09-300001479290us-gaap:CommercialPaperMember2020-12-310001479290rvnc:CorporateBondMember2021-09-300001479290rvnc:CorporateBondMember2020-12-310001479290us-gaap:CashEquivalentsMember2021-09-300001479290us-gaap:CashEquivalentsMember2020-12-310001479290us-gaap:OtherCurrentAssetsMember2021-09-300001479290us-gaap:OtherCurrentAssetsMember2020-12-310001479290us-gaap:DistributionRightsMember2021-01-012021-09-300001479290us-gaap:DistributionRightsMember2021-09-300001479290us-gaap:DistributionRightsMember2020-01-012020-12-310001479290us-gaap:DistributionRightsMember2020-12-310001479290us-gaap:DevelopedTechnologyRightsMember2021-01-012021-09-300001479290us-gaap:DevelopedTechnologyRightsMember2021-09-300001479290us-gaap:DevelopedTechnologyRightsMember2020-01-012020-12-310001479290us-gaap:DevelopedTechnologyRightsMember2020-12-310001479290us-gaap:InProcessResearchAndDevelopmentMember2021-09-300001479290us-gaap:InProcessResearchAndDevelopmentMember2020-12-310001479290us-gaap:CustomerRelatedIntangibleAssetsMember2021-01-012021-09-300001479290us-gaap:CustomerRelatedIntangibleAssetsMember2021-09-300001479290us-gaap:CustomerRelatedIntangibleAssetsMember2020-01-012020-12-310001479290us-gaap:CustomerRelatedIntangibleAssetsMember2020-12-310001479290us-gaap:TrademarksAndTradeNamesMember2021-01-012021-09-300001479290us-gaap:TrademarksAndTradeNamesMember2021-09-300001479290us-gaap:TrademarksAndTradeNamesMember2020-01-012020-12-310001479290us-gaap:TrademarksAndTradeNamesMember2020-12-310001479290rvnc:AmortizationMember2021-07-012021-09-300001479290rvnc:AmortizationMember2020-07-012020-09-300001479290rvnc:AmortizationMember2021-01-012021-09-300001479290rvnc:AmortizationMember2020-01-012020-09-300001479290us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300001479290us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300001479290us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300001479290us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300001479290rvnc:ResearchAndManufacturingEquipmentMember2021-09-300001479290rvnc:ResearchAndManufacturingEquipmentMember2020-12-310001479290us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-09-300001479290us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-12-310001479290us-gaap:LeaseholdImprovementsMember2021-09-300001479290us-gaap:LeaseholdImprovementsMember2020-12-310001479290us-gaap:ComputerEquipmentMember2021-09-300001479290us-gaap:ComputerEquipmentMember2020-12-310001479290us-gaap:ConstructionInProgressMember2021-09-300001479290us-gaap:ConstructionInProgressMember2020-12-310001479290us-gaap:FurnitureAndFixturesMember2021-09-300001479290us-gaap:FurnitureAndFixturesMember2020-12-310001479290rvnc:PlatformSoftwareMember2021-07-012021-09-300001479290rvnc:PlatformSoftwareMember2021-01-012021-09-300001479290us-gaap:CreditRiskContractMemberrvnc:ValeantPharmaceuticalsInternationalInc.Member2021-09-300001479290us-gaap:CreditRiskContractMemberrvnc:MedicisPharmaceuticalCorporationMember2021-09-300001479290us-gaap:CreditRiskContractMemberrvnc:MedicisPharmaceuticalCorporationMemberus-gaap:MeasurementInputExpectedTermMember2021-01-012021-09-30xbrli:pure0001479290us-gaap:CreditRiskContractMemberrvnc:MedicisPharmaceuticalCorporationMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-01-012021-09-300001479290us-gaap:CreditRiskContractMemberus-gaap:MeasurementInputEntityCreditRiskMemberrvnc:MedicisPharmaceuticalCorporationMember2021-01-012021-09-300001479290us-gaap:CreditRiskContractMemberrvnc:MedicisPharmaceuticalCorporationMember2020-12-310001479290us-gaap:CreditRiskContractMemberrvnc:MedicisPharmaceuticalCorporationMemberus-gaap:MeasurementInputExpectedTermMember2020-01-012020-12-310001479290us-gaap:CreditRiskContractMemberrvnc:MedicisPharmaceuticalCorporationMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-01-012020-12-310001479290us-gaap:CreditRiskContractMemberus-gaap:MeasurementInputEntityCreditRiskMemberrvnc:MedicisPharmaceuticalCorporationMember2020-01-012020-12-310001479290srt:MinimumMember2021-09-300001479290srt:MaximumMember2021-09-30rvnc:option_to_extend_lease_term00014792902021-04-012021-04-300001479290rvnc:LyophilizationServicesOfNewEnglandIncMember2021-04-012021-04-30utr:sqft0001479290rvnc:NashvilleLeaseExpansionPremisesMember2021-07-310001479290rvnc:TwentyTwentySevenNotesMemberus-gaap:ConvertibleDebtMember2020-02-140001479290rvnc:TwentyTwentySevenNotesMemberus-gaap:ConvertibleDebtMember2020-02-142020-02-14rvnc:trading_day0001479290rvnc:DebtConversionTermsOneMemberrvnc:TwentyTwentySevenNotesMemberus-gaap:ConvertibleDebtMember2020-02-142020-02-140001479290rvnc:TwentyTwentySevenNotesMemberrvnc:DebtConversionTermsTwoMemberus-gaap:ConvertibleDebtMember2020-02-142020-02-140001479290rvnc:TwentyTwentySevenNotesMemberus-gaap:ConvertibleDebtMember2020-12-310001479290rvnc:TwentyTwentySevenNotesMemberus-gaap:ConvertibleDebtMember2020-01-012020-12-310001479290rvnc:TwentyTwentySevenNotesMemberus-gaap:ConvertibleDebtMember2021-09-3000014792902020-02-142020-02-1400014792902020-02-140001479290rvnc:TwoThousandAndFourteenEquityIncentivePlanMember2021-01-010001479290rvnc:TwoThousandAndFourteenEquityIncentivePlanMemberus-gaap:StockCompensationPlanMember2021-01-012021-09-300001479290rvnc:TwoThousandAndFourteenEquityIncentivePlanMemberus-gaap:RestrictedStockMember2021-01-012021-09-300001479290rvnc:TwoThousandAndFourteenEquityIncentivePlanMemberus-gaap:PerformanceSharesMember2021-01-012021-09-300001479290rvnc:TwoThousandAndFourteenEquityIncentivePlanMember2021-09-300001479290rvnc:TwoThousandAndFourteenInducementPlanMemberus-gaap:EmployeeStockOptionMember2021-01-012021-09-300001479290rvnc:TwoThousandAndFourteenInducementPlanMember2021-09-300001479290rvnc:A2017EquityIncentivePlanHintMDPlanMemberrvnc:HintMDMember2020-07-230001479290rvnc:A2017EquityIncentivePlanHintMDPlanMember2021-01-012021-09-300001479290rvnc:A2017EquityIncentivePlanHintMDPlanMember2021-09-300001479290rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2021-01-010001479290rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2021-09-300001479290us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-09-300001479290us-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-09-300001479290us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001479290us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001479290us-gaap:RestrictedStockMember2021-01-012021-09-300001479290us-gaap:RestrictedStockMember2020-01-012020-09-300001479290rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMemberus-gaap:EmployeeStockOptionMember2021-01-012021-09-300001479290rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMemberus-gaap:EmployeeStockOptionMember2020-01-012020-09-300001479290rvnc:AttheMarketOfferingMember2020-11-012020-11-300001479290rvnc:AttheMarketOfferingMember2021-01-012021-09-300001479290srt:WeightedAverageMemberrvnc:AttheMarketOfferingMember2021-09-3000014792902021-02-252021-09-300001479290rvnc:AttheMarketOfferingMember2020-01-012020-12-310001479290srt:WeightedAverageMemberrvnc:AttheMarketOfferingMember2020-12-310001479290rvnc:AttheMarketOfferingMember2021-09-300001479290us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001479290us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001479290us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001479290us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:CorporateBondMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:CorporateBondMemberus-gaap:FairValueInputsLevel1Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberrvnc:CorporateBondMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:CorporateBondMemberus-gaap:FairValueInputsLevel3Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:DerivativeLiabilitySettlementMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:DerivativeLiabilitySettlementMemberus-gaap:FairValueInputsLevel1Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberrvnc:DerivativeLiabilitySettlementMember2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:DerivativeLiabilitySettlementMemberus-gaap:FairValueInputsLevel3Member2021-09-300001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:DerivativeLiabilitySettlementMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:DerivativeLiabilitySettlementMemberus-gaap:FairValueInputsLevel1Member2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberrvnc:DerivativeLiabilitySettlementMember2020-12-310001479290us-gaap:FairValueMeasurementsRecurringMemberrvnc:DerivativeLiabilitySettlementMemberus-gaap:FairValueInputsLevel3Member2020-12-310001479290rvnc:DerivativeLiabilitySettlementMember2020-12-310001479290rvnc:DerivativeLiabilitySettlementMember2021-01-012021-09-300001479290rvnc:DerivativeLiabilitySettlementMember2021-09-300001479290rvnc:TeoxaneAgreementMember2020-01-012020-01-310001479290rvnc:TeoxaneAgreementMember2021-01-012021-09-300001479290us-gaap:CreditRiskContractMemberrvnc:ListLaboratoriesMember2021-09-300001479290rvnc:BotulinumToxinResearchAssociatesInc.Member2021-09-30rvnc:segment0001479290us-gaap:IntersegmentEliminationMember2021-07-012021-09-300001479290us-gaap:IntersegmentEliminationMember2021-01-012021-09-300001479290us-gaap:IntersegmentEliminationMember2020-07-012020-09-300001479290us-gaap:IntersegmentEliminationMember2020-01-012020-09-300001479290rvnc:ProductSegmentMember2021-07-012021-09-300001479290rvnc:ProductSegmentMember2020-07-012020-09-300001479290rvnc:ProductSegmentMember2021-01-012021-09-300001479290rvnc:ProductSegmentMember2020-01-012020-09-300001479290rvnc:ServiceSegmentMember2021-07-012021-09-300001479290rvnc:ServiceSegmentMember2020-07-012020-09-300001479290rvnc:ServiceSegmentMember2021-01-012021-09-300001479290rvnc:ServiceSegmentMember2020-01-012020-09-300001479290rvnc:ProductSegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300001479290rvnc:ProductSegmentMemberus-gaap:OperatingSegmentsMember2020-07-012020-09-300001479290rvnc:ProductSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300001479290rvnc:ProductSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-300001479290us-gaap:OperatingSegmentsMemberrvnc:ServiceSegmentMember2021-07-012021-09-300001479290us-gaap:OperatingSegmentsMemberrvnc:ServiceSegmentMember2020-07-012020-09-300001479290us-gaap:OperatingSegmentsMemberrvnc:ServiceSegmentMember2021-01-012021-09-300001479290us-gaap:OperatingSegmentsMemberrvnc:ServiceSegmentMember2020-01-012020-09-300001479290us-gaap:CorporateNonSegmentMember2021-07-012021-09-300001479290us-gaap:CorporateNonSegmentMember2020-07-012020-09-300001479290us-gaap:CorporateNonSegmentMember2021-01-012021-09-300001479290us-gaap:CorporateNonSegmentMember2020-01-012020-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___ to ___
Commission File No. 001-36297
Revance Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware77-0551645
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification No.)

1222 Demonbreun Street, Suite 2000, Nashville, Tennessee, 37203
(Address, including zip code, of principal executive offices)

(615) 724-7755
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareRVNCNasdaq Global Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filerEmerging growth company
Non-accelerated filerSmaller reporting company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial statement accounting standards provide pursuance to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐    No  ý
Number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of October 28, 2021: 71,794,852


Table of Contents
 
  Page
PART I. FINANCIAL INFORMATION
Item 1.
 
 
 
 
 
Item 2.
Item 3.
Item 4.
PART II. OTHER INFORMATION
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

“Revance TherapeuticsTM,” the Revance logos and other trademarks or service marks of Revance appearing in this quarterly report on Form 10-Q (this “Report”) are the property of Revance Therapeutics, Inc. OPULTM is the property of Hint, Inc., a wholly owned subsidiary of Revance Therapeutics, Inc. This Report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.
Unless expressly indicated or the context requires otherwise, the terms “Revance,” “company,” “we,” “us,” and “our,” in this document refer to Revance Therapeutics, Inc., a Delaware corporation, and, where appropriate, its wholly owned subsidiaries.



Table of Contents
PART I.FINANCIAL INFORMATION

ITEM 1. Condensed Consolidated Financial Statements (Unaudited)

REVANCE THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
 September 30,December 31,
 20212020
ASSETS
CURRENT ASSETS
Cash and cash equivalents$127,177 $333,558 
Short-term investments146,504 102,947 
Accounts receivable, net1,658 1,829 
Inventories10,192 5,876 
Prepaid expenses and other current assets8,352 5,793 
Total current assets293,883 450,003 
Property and equipment, net22,029 17,499 
Goodwill146,964 146,964 
Intangible assets, net59,491 71,343 
Operating lease right of use assets45,533 29,632 
Restricted cash5,057 3,445 
Other non-current assets8,871 1,334 
TOTAL ASSETS$581,828 $720,220 
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable$8,038 $12,657 
Accruals and other current liabilities38,887 32,938 
Deferred revenue, current10,941 7,851 
Operating lease liabilities, current4,829 4,437 
Derivative liability3,179 3,081 
Total current liabilities65,874 60,964 
Convertible senior notes280,319 180,526 
Deferred revenue, non-current73,757 77,294 
Operating lease liabilities, non-current40,466 27,146 
Other non-current liabilities1,250  
TOTAL LIABILITIES461,666 345,930 
Commitments and Contingencies (Note 13)
STOCKHOLDERS’ EQUITY
Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2021 and December 31, 2020
  
Common stock, par value $0.001 per share — 190,000,000  and 95,000,000 shares authorized as of September 30, 2021 and December 31, 2020, respectively; 71,838,777 and 69,178,666 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively
72 69 
Additional paid-in capital1,454,947 1,500,514 
Accumulated other comprehensive loss(3) 
Accumulated deficit(1,334,854)(1,126,293)
TOTAL STOCKHOLDERS’ EQUITY120,162 374,290 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$581,828 $720,220 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

Table of Contents

REVANCE THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Revenue
Product revenue$18,296 $2,819 $46,982 $2,868 
Collaboration revenue1,129 808 4,034 1,116 
Service revenue320 208 832 208 
Total revenue19,745 3,835 51,848 4,192 
Operating expenses:
Cost of product revenue (exclusive of amortization)5,827 1,081 15,453 1,102 
Cost of service revenue (exclusive of amortization)59 4 76 4 
Selling, general and administrative52,782 48,183 152,385 99,013 
Research and development30,095 29,130 86,787 96,027 
Amortization3,705 2,565 10,219 3,239 
Total operating expenses92,468 80,963 264,920 199,385 
Loss from operations(72,723)(77,128)(213,072)(195,193)
Interest income84 413 266 2,868 
Interest expense(1,571)(4,334)(4,700)(10,738)
Changes in fair value of derivative liability(20)(62)(98)(211)
Other expense, net(146)(146)(608)(406)
Loss before income taxes(74,376)(81,257)(218,212)(203,680)
Income tax provision   (100)
Net loss(74,376)(81,257)(218,212)(203,780)
Unrealized loss and adjustment on securities included in net loss(1)(117)(3)(3)
Comprehensive loss$(74,377)$(81,374)$(218,215)$(203,783)
Basic and diluted net loss$(74,376)$(81,257)$(218,212)$(203,780)
Basic and diluted net loss per share$(1.10)$(1.34)$(3.24)$(3.62)
Basic and diluted weighted-average number of shares used in computing net loss per share67,782,033 60,526,740 67,297,954 56,233,093 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

Table of Contents
REVANCE THERAPEUTICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(In thousands, except share and per share amounts)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
SharesAmountSharesAmountSharesAmountSharesAmount
Convertible Preferred Stock $  $  $  $ 
Common Stock
Balance — Beginning of period71,798,624 72 57,313,556 57 69,178,666 69 52,374,735 52 
Issuance of restricted stock awards and performance stock awards, net of cancellation99,965 — 1,170,500 1 1,136,221 1 2,588,353 2 
Issuance of common stock in connection with at-the-market offerings— — — — 761,526 1 — — 
Issuance of common stock upon exercise of stock options and warrants41,900 — 511,049 1 921,376 1 587,843 1 
Issuance of common stock relating to employee stock purchase plan— — — — 91,562 — 48,661 — 
Shares withheld related to net settlement of restricted stock awards(101,712)— (178,005)— (250,574)— (257,492)— 
Issuance of common stock in connection with the Teoxane Agreement— — — — — — 2,500,000 3 
Issuance of common stock in connection with offerings— — — — — — 975,000 1 
Issuance of common stock in connection with the HintMD Acquisition— — 7,770,613 8 — — 7,770,613 8 
Balance — End of period71,838,777 72 66,587,713 67 71,838,777 72 66,587,713 67 
Additional Paid-In Capital
Balance — Beginning of period 1,446,643  1,222,271  1,500,514  1,069,639 
Cumulative-effect adjustment from adoption of ASU 2020-06— — — — — (108,509)— — 
Issuance of restricted stock awards and performance stock awards, net of cancellation— — — (1)— (1)— (2)
Issuance of common stock in connection with at-the-market offerings, net of issuance costs— (70)— — — 21,553 — — 
Issuance of common stock upon exercise of stock options and warrants— 314 — 3,805 — 12,823 — 4,804 
Issuance of common stock relating to employee stock purchase plan— — — — — 2,206 — 671 
Shares withheld related to net settlement of restricted stock awards— (2,694)— (4,493)— (6,944)— (6,005)
Stock-based compensation— 10,754 — 11,092 — 33,305 — 24,989 
Equity component of convertible senior notes— — — — — — — 108,510 
Issuance of common stock in connection with the Teoxane Agreement— — — — — — — 43,397 
Issuance of common stock in connection with offerings, net of issuance costs of $44
— — — — — — — 15,536 
Capped call transactions related to the issuance of convertible senior notes— — — — — — — (28,865)
Issuance of common stock and awards assumed in connection with the HintMD Acquisition— — — 188,096 — — — 188,096 
Balance — End of period $1,454,947  $1,420,770  $1,454,947  $1,420,770 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

Table of Contents
REVANCE THERAPEUTICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity—(Continued)
(In thousands, except share and per share amounts)
(Unaudited) 


Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
SharesAmountSharesAmountSharesAmountSharesAmount
Other Accumulated Comprehensive Gain (Loss)
Balance — Beginning of period (2) 117    3 
Unrealized gain (loss) and adjustment on securities included in net loss— (1)— (117)— (3)— (3)
Balance — End of period (3)   (3)  
Accumulated Deficit
Balance — Beginning of period (1,260,478) (966,727) (1,126,293) (844,204)
Cumulative-effect adjustment from adoption of ASU 2020-06— — — — — 9,651 — — 
Net loss— (74,376)— (81,257)— (218,212)— (203,780)
Balance — End of period (1,334,854) (1,047,984) (1,334,854) (1,047,984)
Total Stockholders’ Equity71,838,777 $120,162 66,587,713 $372,853 71,838,777 $120,162 66,587,713 $372,853 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

Table of Contents
REVANCE THERAPEUTICS, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited) 
 Nine Months Ended September 30,
 20212020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss$(218,212)$(203,780)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation32,513 24,574 
Depreciation and amortization14,434 5,931 
Amortization of debt discount and issuance costs935 7,576 
Amortization of discount on investments(16)(1,351)
Other non-cash operating activities140 474 
Non-cash in-process research and development 11,184 
Changes in operating assets and liabilities:
Accounts receivable171 (2,492)
Inventories(4,316)(3,976)
Prepaid expenses and other current assets5,141 (1,254)
Operating lease right of use assets(15,901)1,085 
Other non-current assets(7,537)515 
Accounts payable(4,578)147 
Accruals and other liabilities5,784 17,142 
Deferred revenue(447)29,883 
Operating lease liabilities13,712 (1,846)
Other non-current liabilities1,250  
Net cash used in operating activities(176,927)(116,188)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments(178,588)(239,821)
Finance lease prepayments(7,700) 
Purchases of property and equipment(6,018)(1,890)
Proceeds from maturities of investments135,000 246,500 
Proceeds from sale of investments 16,969 
Cash paid for HintMD Acquisition, net (818)
Purchase of intangible assets (118)
Net cash provided by (used in) investing activities(57,306)20,822 
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock in connection with at-the-market offerings, net of commissions21,706  
Proceeds from the exercise of stock options, common stock warrants and employee stock purchase plan15,029 5,476 
Taxes paid related to net settlement of restricted stock awards(6,944)(6,005)
Payment of offering costs(327)(337)
Proceeds from issuance of convertible senior notes 287,500 
Proceeds from issuance of common stock in connection with offerings, net of commissions and discount 15,581 
Payment of capped call transactions (28,865)
Payment of convertible senior notes transaction costs (9,190)
Net cash provided by financing activities29,464 264,160 
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH(204,769)168,794 
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period337,003 171,890 
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period$132,234 $340,684 
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Property and equipment purchases included in accounts payable and accruals$1,206 $336 
Internally developed software capitalized from stock-based compensation$792 $415 
Issuance of common stock and awards assumed in connection with the HintMD Acquisition$ $188,104 
Issuance of common stock in connection with the Teoxane Agreement$ $43,400 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7

Table of Contents
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. The Company and Summary of Significant Accounting Policies
The Company
Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and are pursuing United States (“U.S.”) regulatory approval. We are also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar (frown) lines, forehead lines and crow’s feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, we own a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to Teoxane SA (“Teoxane”)’s line of Resilient Hyaluronic Acid® (“RHA®”) Collection of dermal fillers, the first and only range of U.S. Food and Drug Administration (the “FDA”)-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL™ Relational Commerce Platform (“OPUL™”). We have also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX® (“an onabotulinumtoxinA biosimilar”), which would compete in the existing short-acting neuromodulator marketplace.
Since inception, we have devoted substantial efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, the onabotulinumtoxinA biosimilar, and the commercial launch of our products and services. As a result, we have incurred losses and negative cash flows from operations. We have not generated substantial revenue to date, and will continue to incur significant research and development, sales and marketing, and other expenses related to our ongoing operations.
Liquidity and Going Concern Assessment
For the three and nine months ended September 30, 2021, we had a net loss of $74.4 million and $218.2 million, respectively. As of September 30, 2021, we had working capital surplus of $228.0 million and an accumulated deficit of $1.3 billion. In recent years, we have funded our operations primarily through the sale of common stock, convertible senior notes, payments received from collaboration arrangements, and sales of the RHA® Collection of dermal fillers. As of September 30, 2021, we had capital resources of $273.7 million consisting of cash, cash equivalents, and short-term investments.
On October 15, 2021, the FDA issued a Complete Response Letter (“CRL”) regarding our BLA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines. The FDA indicated it was unable to approve the BLA in its present form due to deficiencies related to the FDA’s onsite inspection at our manufacturing facility. As a result, the potential commercial launch of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines has been delayed. Absent deferring and reducing certain costs previously planned as well as other mitigating actions, the commercial launch delay and its impact on our capital resources would raise substantial doubt with respect to our ability to meet our obligations to continue as a going concern within one year following the filing of this Report.
Despite the delay in approval and in consideration of the cash preservation measures management has identified, we believe that our existing cash, cash equivalents, and short-term investments will allow us to fund our operations for at least 12 months following the filing of this Report while we continue to work with the FDA for the potential approval of our BLA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines. Our plan to preserve cash in order to fund our operations for at least 12 months following the filing of this Report includes, but is not limited to: pausing non-critical hires; deferring the Phase 3 clinical program for upper limb spasticity and other therapeutics pipeline
8

Table of Contents
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
activities; and deferring international regulatory and commercial investment for DaxibotulinumtoxinA for Injection. Our plans contemplate continued support for our partnership with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
The condensed consolidated financial statements have been prepared on a going-concern basis. The condensed consolidated financial statements do not include any adjustments relating to any of the foregoing uncertainties.
Basis of Presentation and Principles of Consolidation
The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented.
Our condensed consolidated balance sheet for the year ended December 31, 2020 was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2021, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the “SEC”), on February 25, 2021.
Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. All intercompany transactions have been eliminated.
Use of Estimates & Risks and Uncertainties
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, the fair value of assets and liabilities assumed in business combinations, the incremental borrowing rate used to measure operating lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals for clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, the fair value of derivative liability, and income taxes.
The full extent of the impact of the COVID-19 pandemic on the Company’s future operational and financial performance is currently uncertain. The ongoing COVID-19 pandemic has caused a global slowdown of economic activity which has negatively impacted consumer spending, including with respect to our current and potential customers, while also disrupting sales channels and marketing activities. The extent to which the COVID-19 pandemic will further directly or indirectly impact our business, results of operations, financial condition, and liquidity will depend on future developments that are highly uncertain, including variant strains of the virus and the degree of their vaccine resistance and as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects. The FDA was previously unable to conduct the required inspection of our manufacturing facility in Northern California, due to the FDA’s travel restrictions associated with the COVID-19 pandemic. Although the FDA inspection process has taken place and we have responded to the FDA’s observations from the inspection, we cannot be certain of how long it will take to remediate deficiencies identified by the FDA during the inspection and respond to the FDA or how quickly or successfully the regulatory approval process will move following our remediation of the deficiencies and our response to the FDA or the future impact of the COVID-19 pandemic on the submissions related to DaxibotulinumtoxinA for Injection in indications outside of glabellar (frown) lines, the progress of clinical trials, supplies and sales of the RHA® Collection of dermal fillers, demand for our products and other aspects of our operations.
9

Table of Contents
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.
Recently Adopted Accounting Pronouncement
In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible debt instruments by removing certain requirements to separately account for conversion options embedded in debt instruments that are not required to be accounted for as derivative instruments. ASU 2020-06 also updates and improves the consistency of earnings per share calculations for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. On January 1, 2021, we adopted ASU 2020-06 using the modified retrospective method, and the adoption did not have any impact on our consolidated balance sheets as of December 31, 2020. As a result of the adoption, on January 1, 2021, we made certain adjustments to our consolidated balance sheets which consisted of an increase of $98.9 million in Convertible Senior Notes (the 2027 Notes as defined in Note 10), a decrease of $108.5 million in Additional Paid-in Capital and a decrease of $9.7 million in Accumulated Deficit. Additionally, from January 1, 2021, we will no longer incur non-cash interest expense for the amortization of debt discount after adoption, therefore the interest expense for the 2027 Notes, which is included in the “interest expense” on the condensed consolidated statements of operations and comprehensive loss, will be lower compared to fiscal year 2020.

10

Table of Contents
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
2. Revenue    
Our revenue is primarily generated from U.S. customers. Our product and collaboration revenue is generated from the Product Segment, and our service revenue is generated from the Service Segment (Note 14). The following tables present our revenues disaggregated by the timing of transfer of goods or services:
Three Months Ended September 30, 2021Nine Months Ended September 30, 2021
(in thousands)Product RevenueCollaboration RevenueService RevenueTotalProduct RevenueCollaboration RevenueService RevenueTotal
Timing of revenue recognition:
Transferred at a point in time
$18,296 $ $166 $18,462 $46,982 $ $379 $47,361 
Transferred over time 1,129 154 1,283  4,034 453 4,487 
Total$18,296 $1,129 $320 $19,745 $46,982 $4,034 $832 $51,848 
Three Months Ended September 30, 2020Nine Months Ended September 30, 2020
(in thousands)Product RevenueCollaboration RevenueService RevenueTotalProduct RevenueCollaboration RevenueService RevenueTotal
Timing of revenue recognition:
Transferred at a point in time
$2,819 $ $ $2,819 $2,868 $ $ $2,868 
Transferred over time 808 208 1,016  1,116 208 1,324 
Total$2,819 $808 $208 $3,835 $2,868 $1,116 $208 $4,192 
Product Revenue
For the three and nine months ended September 30, 2021, all product revenue was generated from the sale of the RHA® Collection of dermal fillers.
Receivables and contract liabilities from contracts with our product revenue customers are as follows:
September 30,December 31,
(in thousands)20212020
Accounts receivables, net$1,577 $1,687 
Contract liabilities:
Deferred revenue, current$(1,617)$ 
Total contract liabilities$(1,617)$ 
Collaboration Revenue
Viatris Collaboration and License Agreement
Agreement Terms
We entered into a collaboration and license agreement with Viatris (the “Viatris Collaboration”) in February 2018, pursuant to which we are collaborating with Viatris exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize an onabotulinumtoxinA biosimilar.
Viatris has paid us an aggregate of $60 million in non-refundable fees as of September 30, 2021, and the agreement provides for additional remaining contingent payments of up to $70 million upon the achievement of certain clinical and
11

Table of Contents
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
regulatory milestones and up to $225 million upon specified, tiered sales milestones. The payments do not represent a financing component for the transfer of goods or services. In addition, Viatris is required to pay us low to mid-double digit royalties on any sales of the biosimilar in the U.S., mid-double digit royalties on any sales in Europe, and high single digit royalties on any sales in other ex-U.S. Viatris territories. However, we have agreed to waive royalties for U.S. sales, up to a maximum of $50 million in annual sales, during the first approximately four years after commercialization to defray launch costs.
Revenue Recognition
We re-evaluate the transaction price at each reporting period. We estimated the transaction price for the Viatris Collaboration using the most likely amount method. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Viatris. Other than the upfront payment, all other milestones and consideration we may earn under the Viatris Collaboration are subject to uncertainties related to development achievements, Viatris’ rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license and the license is the predominant feature in the Viatris Collaboration. As of September 30, 2021, the transaction price allocated to the unfulfilled performance obligations was $100.3 million.
We recognize revenue and estimate deferred revenue based on the cost of development service incurred over the total estimated cost of development service to be provided for the development period. For revenue recognition purposes, the development period is estimated to continue through 2025. It is possible that this period will change and is assessed at each reporting date.
For the three and nine months ended September 30, 2021, we recognized revenue related to development services of $1.1 million and $4.0 million, respectively. For the three and nine months ended September 30, 2020, we recognized revenue related to development services of $0.8 million and $1.1 million, respectively.
Fosun License Agreement
Agreement Terms
In December 2018, we entered into a license agreement (the “Fosun License Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), whereby we granted Fosun the exclusive rights to develop and commercialize DaxibotulinumtoxinA for Injection in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights.
Fosun has paid us non-refundable upfront and other payments totaling $31 million before foreign withholding taxes. We are also eligible to receive (i) additional remaining contingent payments of up to $229.5 million upon the achievement of certain milestones based on (a) the approval of BLAs for certain aesthetic and therapeutic indications and (b) first calendar year net sales, and (ii) tiered royalty payments in low double digits to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) we do not have any valid and unexpired patent claims that cover the product in the Fosun Territory, (ii) biosimilars of the product are sold in the Fosun Territory or (iii) Fosun needs to pay compensation to third parties to either avoid patent infringement or market the product in the Fosun Territory.
Revenue Recognition
We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of September 30, 2021, the transaction price allocated to unfulfilled performance obligation was $31 million.
12

Table of Contents
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
For the three and nine months ended September 30, 2021 and 2020, no revenue was recognized from the Fosun License Agreement.
Contract liabilities from contracts with our collaboration revenue customers are as follows:
September 30,December 31,
(in thousands)20212020
Contract liabilities:
Deferred revenue, current - Viatris$9,317 $7,851 
Total contract liabilities, current$9,317 $7,851 
Deferred revenue, non-current - Viatris$42,762 $46,299 
Deferred revenue, non-current - Fosun30,995 30,995 
Total contract liabilities, non-current$73,757 $77,294 
Changes in our contract liabilities from contracts with our collaboration revenue customers for the nine months ended September 30, 2021 are as follows:
(in thousands)
Balance on January 1, 2021$85,145 
Revenue recognized(4,034)
Billings and adjustments, net1,963 
Balance on September 30, 2021$83,074 
Service Revenue
On July 23, 2020, we completed the acquisition of all of the issued and outstanding shares of Hint, Inc. (d/b/a HintMD) (the “HintMD Acquisition”), and HintMD became a wholly owned subsidiary of Revance. Following the HintMD Acquisition, we began to offer customer payment processing and certain value-added services through the HintMD Platform to aesthetic practices. We also commercially launched OPUL™, the next-generation fintech platform (together with the HintMD Platform, the “Fintech Platform”), in October 2021. The Fintech Platform has not generated material revenue to date. Generally, revenue related to the payment processing service is recognized at a point in time, whereas revenue related to the value-added services is recognized over time.

Receivables and contract assets from contracts with our service revenue customers are as follows:
September 30,December 31,
(in thousands)20212020
Accounts receivables, net$81 $142 
Contract assets:
Contract assets, current$148 $30 
Contract assets, non-current359 85 
Total contract assets$507 $115 

3. Business Acquisition
On July 23, 2020, we completed the HintMD Acquisition, and HintMD became a wholly-owned subsidiary of Revance. The following supplemental unaudited pro forma financial information presents the combined results of operations for each of the periods presented, as if the HintMD Acquisition occurred on January 1, 2019. The pro forma financial information is presented for illustrative purposes only, based on currently available information and certain estimates and
13

Table of Contents
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
assumptions we believe are reasonable under the circumstances, and is not necessarily indicative of future results of operations or the results that would have been reported if the HintMD Acquisition had been completed on January 1, 2019. These results were not used as a part of our analysis of the financial results and performance of the business. These results are adjusted and do not include any anticipated synergies or other expected benefits of the acquisition.
 Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)20202020
Total revenue$3,863 $4,633 
Net loss$(83,008)$(216,312)

Significant non-recurring pro forma adjustments include the following:
Transaction costs of $3.9 million were assumed to have been incurred on January 1, 2019 and were recognized as if incurred in the first quarter of 2019.
Share-based compensation expense of $1.3 million was assumed to have been incurred on January 1, 2019 and was recognized as if incurred in the first quarter of 2019. Such share-based compensation was related to stock awards held by HintMD employees prior to July 23, 2020 that have been assumed and converted into our stock awards.

4. Cash Equivalents and Short-Term Investments
The following table is a summary our cash equivalents and short-term investments:
September 30, 2021December 31, 2020
Unrealized
in thousandsCostLossFair ValueCostFair Value
Money market funds$114,267 $ $114,267 $267,130 $267,130 
Commercial paper124,914  124,914 113,446 113,446 
Corporate bonds21,593 (3)21,590   
Total cash equivalents and available-for-sale securities$260,774 $(3)$260,771 $380,576 $380,576 
Classified as:
Cash equivalents$114,267 $277,629 
Short-term investments146,504 102,947 
Total cash equivalents and available-for-sale securities$260,771 $380,576 
As of September 30, 2021 and December 31, 2020, we have no other-than-temporary impairments on our available-for-sale securities and the contractual maturities of the available-for-sale securities are less than one-year.

14

Table of Contents
REVANCE THERAPEUTICS, INC.
Notes to Condensed Consolidated Financial Statements — (Continued)
(Unaudited)
5. Intangible Assets, net
The following table sets forth the intangible assets and the remaining useful lives for the intangible assets:
September 30, 2021December 31, 2020
(in thousands, except for in years)Weighted-Average Remaining Useful Lives
(in years)
Gross Carrying AmountAccumulated AmortizationNet Carrying AmountRemaining Useful Lives
(in years)
Gross Carrying AmountAccumulated AmortizationNet Carrying Amount
Distribution rights2.7$32,334 $(10,778)$21,556 3.4$32,334 $(4,715)$27,619 
Developed technology5.135,800 (5,161)30,639 5.619,600 (1,362)18,238 
In-process research and development (1)
 N/A  —  N/A16,200 — 16,200 
Customer relationships2.810,300 (3,004)7,296 3.610,300 (1,072)9,228 
Tradename0.0100 (100) 0.6100 (42)58 
Total intangible assets$78,534 $(19,043)$59,491 $78,534 $(7,191)$71,343 
(1)In-process research and development relates to the research and development of the payment facilitator (“PayFac”) technology to facilitate the processing of customer payments. During the nine months ended September 30, 2021, the in-process research and development assets were placed into service and reclassified as developed technology.

Aggregate amortization expense for the intangible assets presented in the condensed consolidated statements of operations and comprehensive loss are summarized as follows:
 Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)2021202020212020
Amortization (1)
$3,512 $2,565 $9,862 $3,239 
Selling, general and administrative653